DNAtrix is a clinical-stage oncolytic immunotherapy company that develops modified viruses for the treatment of cancer. Led by president and CEO Frank Tufaro, Ph.D., the company’s lead product is the oncolytic virus DNX-2401. DNAtrix intends to use newly raised funds to advance DNX-2401 into late-stage clinical trials for glioblastoma. The company completed a $20M Series B equity financing to support that development. DNAtrix is based in Houston, Texas and San Diego, California. The financing also coincided with a board appointment from the lead investor. DNAtrix is a clinical-stage biotech developing genetically modified oncolytic adenoviruses to treat aggressive cancers, with a lead candidate DNX-2401. DNX-2401 selectively kills tumor cells and is currently being evaluated in a Phase Ib trial in combination with temozolomide for recurrent glioblastoma. An earlier Phase I study of DNX-2401 demonstrated an excellent safety profile and promising efficacy, including observations of long-term survival and tumor destruction. The company plans to use newly awarded funds to accelerate clinical development and pursue commercialization for malignant glioma. Financially, DNAtrix was awarded a $10.8 million product development grant from the Cancer Prevention and Research Institute of Texas to support its glioblastoma program. DNAtrix is privately held and headquartered in Houston, Texas.

Total raised

$31M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2014